Clinical Trials Directory

Trials / Completed

CompletedNCT01815450

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
369 (actual)
Sponsor
Braintree Laboratories · Industry
Sex
All
Age
12 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.

Conditions

Interventions

TypeNameDescription
DRUGBLI1100BLI1100 topical cream
DRUGBLI1100 - modified formulationBLI1100 topical cream
DRUGPlaceboPlacebo topical cream

Timeline

Start date
2013-02-01
Primary completion
2013-11-01
First posted
2013-03-21
Last updated
2015-02-02

Locations

15 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01815450. Inclusion in this directory is not an endorsement.

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris (NCT01815450) · Clinical Trials Directory